The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of TriVascular Technologies, Inc. (NASDAQ:TRIV) (“TriVascular” or “the Company”) in connection with the sale of the Company to Endologix, Inc. Under the terms of the transaction, TriVascular shareholders will receive a combination of cash and stock valued at approximately $9.10 per share. Certain insiders possessing approximately 32.5% of the Company’s outstanding shares have already agreed to tender their shares.

Click here to learn about the case: http://docs.wongesq.com/TRIV-Info-Request-Form-967. There is no cost or obligation to you.

The investigation concerns whether the Board of TriVascular breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Endologix underpaying for TriVascular shares.

If you own common stock in TriVascular and wish to obtain additional information, please contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/TRIV-Info-Request-Form-967.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

The Law Offices of Vincent WongVincent Wong, Esq., 212-425-1140Fax: 866-699-3880vw@wongesq.com

TRIVASCULAR TECHNOLOGIES, INC. (NASDAQ:TRIV)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024 Haga Click aquí para más Gráficas TRIVASCULAR TECHNOLOGIES, INC..
TRIVASCULAR TECHNOLOGIES, INC. (NASDAQ:TRIV)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024 Haga Click aquí para más Gráficas TRIVASCULAR TECHNOLOGIES, INC..